Skip to content
approvedImmune & Inflammation

Thymopentin

Also known as: TP-5, Thymopoietin Pentapeptide, Arg-Lys-Asp-Val-Tyr, Timunox, Sintomodulina

Thymopentin (TP-5) is a synthetic pentapeptide corresponding to the active site (residues 32–36) of the 49-amino-acid thymic hormone thymopoietin. With the sequence Arg-Lys-Asp-Val-Tyr, it retains the full immunomodulatory activity of the parent molecule. Thymopentin is approved in several countries (including Italy and China) for immunodeficiency conditions, and it has been clinically used as an adjunct in HIV, rheumatoid arthritis, hepatitis B, and primary immunodeficiencies.

3 cited references·5 researched benefits

Quick Answer

Thymopentin (TP-5) is a synthetic pentapeptide derived from the thymic hormone thymopoietin, representing its minimal active sequence Arg-Lys-Asp-Val-Tyr. It modulates immune function by promoting T-cell differentiation, enhancing CD4/CD8 ratios, and restoring immune balance in immunocompromised patients. Approved in several countries for immunodeficiency conditions, it has been used clinically in HIV, hepatitis B, rheumatoid arthritis, and primary immunodeficiencies.

Key Facts

Mechanism
Thymopentin mimics the immunoregulatory function of thymopoietin by binding to T-cell precursors and promoting their differentiation into mature, functional T-lymphocytes. It enhances CD4+ helper T-cell activity, normalizes CD4/CD8 ratios, stimulates interleukin-2 (IL-2) production, and augments natural killer (NK) cell cytotoxicity. Unlike broad immunostimulants, thymopentin acts as a true immunomodulator — it upregulates depressed immune responses while helping to normalize overactive immune states, likely through its effects on regulatory T-cell populations and cytokine balance.
Research Status
approved
Half-Life
~30 seconds (rapidly degraded but triggers sustained immune signaling)
Molecular Formula
C₃₀H₄₉N₉O₉
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • Restores T-cell function and normalizes CD4/CD8 ratios in immunocompromised patientsstrong
  • Clinical improvement in primary immunodeficiency syndromes when used as adjunct therapymoderate
  • Adjunct benefit in chronic hepatitis B — enhances seroconversion rates when combined with antiviral therapymoderate
  • Reduction in disease activity in rheumatoid arthritis through immune rebalancingmoderate
  • Enhanced vaccine response in elderly and immunosuppressed populationspreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Subcutaneous injection50 mg3× weeklyStandard clinical dosing protocol used in most approved indications. Typical treatment courses last 3–6 months.
Subcutaneous injection1 mgDailyLower-dose research protocol used in some immunomodulatory studies. Less commonly applied clinically.
Intramuscular injection50 mg3× weeklyAlternative to subcutaneous delivery. Used in some clinical settings where IM administration is preferred.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Injection site discomfort, redness, or mild swellingcommon
  • Transient low-grade fever (immune activation response)rare
  • Mild nausea or malaise after initial dosesrare
  • Theoretical risk of autoimmune flare in predisposed individualsserious

Frequently Asked Questions

What is the difference between thymopentin and thymosin alpha-1?
Both are thymus-derived immunomodulatory peptides, but they come from different parent molecules and have distinct mechanisms. Thymopentin (TP-5) is a 5-amino-acid fragment of thymopoietin that primarily promotes T-cell differentiation and normalizes CD4/CD8 ratios. Thymosin alpha-1 is a 28-amino-acid peptide from thymosin fraction 5 that activates dendritic cells via toll-like receptors TLR2 and TLR9 and shifts immune responses toward Th1 dominance. Thymosin alpha-1 has more extensive clinical trial data and is approved in more countries.
Is thymopentin available for clinical use?
Thymopentin is approved and commercially available in several countries including Italy (as Timunox) and China. It is used clinically for primary and secondary immunodeficiencies, as adjunct therapy in chronic hepatitis B, and for certain autoimmune conditions. It is not FDA-approved in the United States, but may be accessible through compounding pharmacies or imported under specific regulatory pathways.
Why does thymopentin work despite having such a short half-life?
Although thymopentin is rapidly degraded in the bloodstream (half-life approximately 30 seconds), it initiates intracellular signaling cascades in T-cell precursors upon binding that persist long after the peptide itself is cleared. These signals drive T-cell maturation, cytokine production, and immune cell activation programs that unfold over days. This is similar to how many peptide hormones trigger sustained biological effects despite brief plasma presence.
Can thymopentin be used for autoimmune conditions?
Yes, thymopentin has been studied and used clinically for rheumatoid arthritis and other autoimmune conditions. As an immunomodulator rather than a pure immunostimulant, it can help rebalance dysfunctional immune responses. It normalizes CD4/CD8 ratios and supports regulatory T-cell function, which may help dampen autoimmune activity. However, there is a theoretical risk of flaring autoimmune conditions in some individuals, so use should be monitored by an immunologist.

References

  1. 1
    Thymopentin (TP-5): biological activities and clinical applications in immunodeficiency(1984)PubMed ↗
  2. 2
    Thymopentin treatment of rheumatoid arthritis: a double-blind, placebo-controlled clinical trial(1986)PubMed ↗
  3. 3
    Thymic peptides in clinical medicine: review of thymopentin, thymosin alpha-1, and thymalin(1987)PubMed ↗

Latest Research

Last updated: 2026-02-19